Ebola virus, a member of the Filoviridae family, is responsible for severe and often fatal hemorrhagic fever in humans. First identified in 1976 during outbreaks in Sudan and the Democratic Republic of Congo, the virus has since caused sporadic but highly concerning outbreaks in Central and West Africa. Ebola virus is transmitted to humans from wildlife and spreads through human-to-human transmission via direct contact with the blood, secretions, organs, or other bodily fluids of infected individuals. Characterized by a high mortality rate, Ebola virus disease (EVD) manifests with symptoms such as fever, severe headaches, muscle pain, and, in advanced stages, internal and external bleeding. The virus has the potential to cause widespread outbreaks, posing significant public health challenges. Preventive measures include early identification, isolation of infected individuals, and the use of protective equipment. There is no specific antiviral treatment for Ebola, but supportive care and prompt medical intervention can improve outcomes. Ongoing research aims to develop vaccines and therapies to better combat this deadly virus and mitigate the impact of future outbreaks. International collaboration and surveillance efforts remain critical in managing and preventing the spread of Ebola virus.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States